Cytomegalovirus glycoprotein vaccine - sanofi pasteur

Drug Profile

Cytomegalovirus glycoprotein vaccine - sanofi pasteur

Latest Information Update: 26 Jul 2015

Price : $50

At a glance

  • Originator Chiron
  • Developer National Institute of Allergy and Infectious Diseases; sanofi pasteur; University of Alabama at Birmingham
  • Class Cytomegalovirus vaccines; Glycopeptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cytomegalovirus infections

Most Recent Events

  • 26 Jul 2015 No recent reports of development identified - Phase-II for Cytomegalovirus infections in USA (IM)
  • 15 Sep 2009 Efficacy data from a phase II trial in Cytomegalovirus infections presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
  • 18 Mar 2009 Interim efficacy and safety data from a phase II trial in Cytomegalovirus infections released by University of Alabama at Birmingham
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top